Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Net Margin (2020 - 2025)

Insight Molecular Diagnostics' Net Margin history spans 6 years, with the latest figure at 4174.62% for Q3 2025.

  • For Q3 2025, Net Margin rose 755843.0% year-over-year to 4174.62%; the TTM value through Sep 2025 reached 1383.33%, up 248339.0%, while the annual FY2024 figure was 3245.14%, 305046.0% down from the prior year.
  • Net Margin for Q3 2025 was 4174.62% at Insight Molecular Diagnostics, down from 1880.69% in the prior quarter.
  • Across five years, Net Margin topped out at 2905.14% in Q4 2022 and bottomed at 14261.19% in Q3 2022.
  • The 5-year median for Net Margin is 1634.7% (2021), against an average of 2661.9%.
  • The largest annual shift saw Net Margin surged 6166383bps in 2021 before it plummeted -1285876bps in 2022.
  • A 5-year view of Net Margin shows it stood at 1849.74% in 2021, then skyrocketed by 57bps to 2905.14% in 2022, then plummeted by -131bps to 905.92% in 2023, then crashed by -150bps to 2262.92% in 2024, then plummeted by -84bps to 4174.62% in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Net Margin are 4174.62% (Q3 2025), 1880.69% (Q2 2025), and 312.02% (Q1 2025).